We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Parent Age May Help Predict AD Biomarker Levels

By LabMedica International staff writers
Posted on 14 Mar 2018
Alzheimer disease (AD) develops during several decades and presymptomatic individuals might be the best candidates for clinical trials, but their identification is challenging because they have no symptoms.

Asymptomatic people with a family history of sporadic AD were more likely to show abnormal cerebrospinal fluid and brain amyloid- biomarkers as they neared their parent’s onset age, indicating that proximity to parental symptom onset may help predict amyloid- biomarker changes.

A team of scientists led by those at McGill University (Montreal, QC, Canada) analyzed amyloid-1-42 (Aβ1-42) in cerebrospinal fluid (CSF) specimens from 101 cognitively unimpaired individuals enrolled in the Presymptomatic Evaluation of Novel or Experimental Treatments for Alzheimer Disease (PREVENT-AD) cohort from September 1, 2011, through November 30, 2016. More...
Along with a subset of the 101 PREVENT-AD participants, analysis included 128 Adult Children Study (ACS) participants (112 of whom underwent CSF measurement and 107 of whom underwent Pittsburgh compound B carbon 11–labeled positron emission tomography (PIB-PET) and 135 Wisconsin Registry for Alzheimer Prevention (WRAP) participants (85 of whom underwent CSF measurement and all of whom underwent PIB-PET).

The scientists found that PREVENT-AD participants nearing their parent’s Alzheimer’s disease onset age had lower CSF amyloid-1-42 levels; this relationship was stronger in APOE4 carriers and women. Among ACS participants, the team observed the same association using PIB-PET data, and using CSF and PIB-PET data also replicated the female sex interaction. Although the findings were not replicated using cross-sectional data among WRAP participants, the link between parent’s Alzheimer’s disease onset age and CSF amyloid- levels and the APOE interaction were replicated using PIB-PET longitudinal data.

Sylvia Villeneuve, PhD, the lead author of the study, said, “The best time window to prevent Alzheimer’s disease is likely when individuals are still asymptomatic, before extensive neuronal degeneration has occurred. Identifying asymptomatic individuals is challenging and expensive, posing significant difficulties for the current generation of clinical trials. In autosomal dominant Alzheimer’s disease, symptom onset is determinable across generations.”

The authors concluded that their results suggest that proximity to parental symptom onset may help estimate Aβ biomarker changes in women or APOE4 carrier asymptomatic individuals with a parental history of sporadic AD. The study was published on February 26, 2018, in the journal JAMA Neurology.

Related Links:
McGill University


Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Automated Biochemical Analyzer
iBC 900
New
Gold Member
Serological Pipets
INTEGRA Serological Pipets
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: A simple blood test could replace surgical biopsies for early detecion of heart transplant rejection (Photo courtesy of Shutterstock)

Blood Test Detects Organ Rejection in Heart Transplant Patients

Following a heart transplant, patients are required to undergo surgical biopsies so that physicians can assess the possibility of organ rejection. Rejection happens when the recipient’s immune system identifies... Read more

Pathology

view channel
Image: Pancreatic cancer diagnosis (Photo courtesy of World Journal of Gastroenterology)

AI-Driven Preliminary Testing for Pancreatic Cancer Enhances Prognosis

Pancreatic cancer poses a major global health threat due to its high mortality rate, with 467,409 deaths and 510,992 new cases reported worldwide in 2022. Often referred to as the "king" of all cancers,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.